Measurement of piperacillin plasma concentrations in cancer patients with suspected infection.

Rachow T, Schlüter V, Bremer-Streck S, Lindig U, Scholl S, Schlattmann P, Kiehntopf M, Hochhaus A, von Lilienfeld-Toal M (2017) Measurement of piperacillin plasma concentrations in cancer patients with suspected infection. Infection 45(5), 629-636.

Abstract

Piperacillin (PIP) in combination with tazobactam is commonly used for anti-infective treatment in cancer patients. PIP exerts a time-dependent killing. Thus, the maintenance of plasma concentrations above a pre-defined target concentration for a pre-defined time may be relevant for optimal efficacy. It is assumed that PIP-plasma concentrations above the clinical breakpoint of the target pathogen [Pseudomonas aeruginosa, clinical breakpoint at minimal inhibitory concentration (MIC) 16 mg/L] should be reached for 100% of the dosing interval or >4xMIC (64 mg/L) for 50% of the dosing interval. Whereas studies in the intensive-care setting have shown underdosing in patients with sepsis, little is known about PIP-plasma concentrations in cancer patients.

Leibniz-HKI-Authors

Tobias Rachow
Verena Schlüter
Marie von Lilienfeld-Toal

Identifier

doi: 10.1007/s15010-017-1026-z

PMID: 28516432